| ABROCITINIB |
Cibinqo® |
PFIZER AUSTRALIA PTY LTD |
Severe atopic dermatitis |
Nov 2024 |
Recommended |
| AMINO ACID FORMULA WITH FAT, CARBOHYDRATE, VITAMINS AND MINERALS WITHOUT PHENYLALANINE |
PKU Easy Microtabs Plus |
ORPHARMA PTY LTD |
Phenylketonuria (PKU) |
Nov 2024 |
Recommended |
| AMINO ACID FORMULA WITH VITAMINS AND MINERALS WITHOUT METHIONINE, THREONINE AND VALINE
AND LOW IN ISOLEUCINE |
MMA/PA explore5™ |
VITAFLO AUSTRALIA PTY LIMITED |
Methylmalonic acidaemia Propionic acidaemia |
Nov 2024 |
Recommended |
| CAPIVASERTIB |
Truqap® |
ASTRAZENECA PTY LTD |
Hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative
(HER2-) locally advanced (unresectable) or metastatic breast cancer |
Nov 2024 |
Not Recommended |
| DROSPIRENONE |
Slinda® |
BESINS HEALTHCARE AUSTRALIA PTY LTD |
Contraception |
Nov 2024 |
Recommended |
| AMINO ACID FORMULA WITH FAT, CARBOHYDRATE, VITAMINS, MINERALS, TRACE ELEMENTS AND
MEDIUM CHAIN TRIGLYCERIDES |
Essential Care Jr |
CORTEX HEALTH PTY LTD |
Combined intolerance to cows' milk protein, soy protein and protein hydrolysate formulae
Severe intestinal malabsorption including short bowel syndrome Eosinophilic oesophagitis
Cows' milk protein enteropathy Severe cows' milk protein enteropathy with failure
to thrive Proven combined immunoglobulin E (IgE) mediated allergy to cows' milk protein
and soy protein Cows' milk anaphylaxis |
Nov 2024 |
Recommended |
| DURVALUMAB OLAPARIB |
Imfinzi® Lynparza® |
ASTRAZENECA PTY LTD |
Advanced, metastatic or recurrent endometrial cancer |
Nov 2024 |
Recommended |
| AMIVANTAMAB |
Rybrevant® |
JANSSEN-CILAG PTY LTD |
Non-small cell lung cancer (NSCLC) |
Nov 2024 |
Recommended |
| TIOTROPIUM |
Spiriva® Respimat® |
BOEHRINGER INGELHEIM PTY LTD |
Severe asthma Bronchospasm and dyspnoea associated with chronic obstructive pulmonary
disease (COPD) |
Nov 2024 |
Recommended |
| ENZALUTAMIDE |
Xtandi® |
ASTELLAS PHARMA AUSTRALIA PTY LTD |
Non-metastatic hormone-sensitive prostate cancer (m0HSPC) |
Nov 2024 |
Not Recommended |
| LANADELUMAB |
Takhzyro® |
TAKEDA PHARMACEUTICALS AUSTRALIA PTY. LTD. |
Hereditary angioedema (HAE) |
Nov 2024 |
Recommended |
| VUTRISIRAN |
Amvuttra® |
MEDISON PHARMA AUSTRALIA PTY LIMITED |
Hereditary transthyretin-mediated (hATTR) amyloidosis |
Nov 2024 |
Recommended |
| PALOVAROTENE |
Sohonos® |
IPSEN PTY LTD |
Fibrodysplasia Ossificans Progressiva (FOP) |
Nov 2024 |
Recommended |
| FINGOLIMOD OFATUMUMAB SIPONIMOD |
Gilenya® Kesimpta® Mayzent® |
NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED |
Multiple sclerosis (MS) |
Nov 2024 |
Recommended |
| TIOTROPIUM WITH OLODATEROL |
Spiolto® Respimat® |
BOEHRINGER INGELHEIM PTY LTD |
Chronic obstructive pulmonary disease (COPD) |
Nov 2024 |
Recommended |
| PEMBROLIZUMAB |
Keytruda® |
MERCK SHARP & DOHME (AUSTRALIA) PTY LTD |
Renal cell carcinoma (RCC) |
Nov 2024 |
Recommended |
| LEUPRORELIN |
Eligard® |
MUNDIPHARMA PTY LIMITED |
Central precocious puberty Locally advanced (stage C) or metastatic (stage D) carcinoma
of the prostate |
Nov 2024 |
Recommended |
| INCLISIRAN |
Leqvio® |
NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED |
Non-familial hypercholesterolaemia Familial heterozygous hypercholesterolaemia |
Nov 2024 |
Recommended |
| FOLLITROPIN ALFA WITH LUTROPIN ALFA |
Pergoveris® |
MERCK HEALTHCARE PTY LTD |
Stimulation of follicular development |
Nov 2024 |
Recommended |
| EPCORITAMAB |
Epkinly® |
ABBVIE PTY LTD |
Relapsed or refractory diffuse large B-cell lymphoma (RR DLBCL) |
Nov 2024 |
Recommended |
| INCLISIRAN |
Leqvio® |
NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED |
Non-familial hypercholesterolaemia Familial heterozygous hypercholesterolaemia |
Nov 2024 |
Recommended |
| IRINOTECAN |
Onivyde® |
SERVIER LABORATORIES (AUST.) PTY. LTD. |
Metastatic pancreatic adenocarcinoma (mPAC) |
Nov 2024 |
Not Recommended |
| MACITENTAN WITH TADALAFIL |
Opsynvi® |
JANSSEN-CILAG PTY LTD |
Pulmonary arterial hypertension (PAH) |
Nov 2024 |
Recommended |
| GARADACIMAB |
Andembry® |
CSL BEHRING (AUSTRALIA) PTY LTD |
Hereditary angioedema (HAE) |
Nov 2024 |
Recommended |
| FENFLURAMINE |
Fintepla® |
UCB AUSTRALIA PROPRIETARY LIMITED |
Seizures associated with Dravet Syndrome |
Nov 2024 |
Recommended |
| OLAPARIB |
Lynparza® |
ASTRAZENECA PTY LTD |
Metastatic castration-resistant prostate cancer (mCRPC) |
Nov 2024 |
Recommended |
| ERENUMAB |
Aimovig® |
NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED |
Chronic migraine |
Nov 2024 |
Recommended |
| NINTEDANIB |
Ofev® |
BOEHRINGER INGELHEIM PTY LTD |
Idiopathic pulmonary fibrosis (IPF) Progressive fibrosing Interstitial lung disease
(PF-ILD) |
Nov 2024 |
Not Recommended |
| PROGESTERONE |
Prometrium® |
BESINS HEALTHCARE AUSTRALIA PTY LTD |
Menopausal hormone therapy |
Nov 2024 |
Recommended |
| RIBOCICLIB |
Kisqali® |
NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED |
Hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative
(HER2-) breast cancer |
Nov 2024 |
Recommended |
| USTEKINUMAB |
Steqeyma® |
CELLTRION HEALTHCARE AUSTRALIA PTY LTD |
Severe chronic plaque psoriasis Severe psoriatic arthritis Severe Crohn disease Complex
refractory fistulising Crohn disease |
Nov 2024 |
Recommended |
| SEMAGLUTIDE |
Ozempic® |
NOVO NORDISK PHARMACEUTICALS PTY. LIMITED |
Diabetes mellitus type 2 (T2DM) |
Nov 2024 |
Recommended |
| TIRZEPATIDE |
- Mounjaro®
- Mounjaro® KwikPen®
|
ELI LILLY AUSTRALIA PTY LTD |
Diabetes mellitus type 2 (T2DM) |
Nov 2024 |
Not Recommended |
| DENOSUMAB |
Jubbonti® Wyost® |
SANDOZ PTY LTD |
Osteoporosis Giant cell tumour of bone Bone metastases |
Nov 2024 |
Recommended |
| ENFORTUMAB VEDOTIN |
Padcev® |
ASTELLAS PHARMA AUSTRALIA PTY LTD |
Locally advanced (Stage III) or metastatic (Stage IV) urothelial cancer (la/mUC) |
Nov 2024 |
Recommended |
| BUDESONIDE |
Budenofalk® |
DR FALK PHARMA AUSTRALIA PTY LTD |
Ulcerative colitis |
Nov 2024 |
Recommended |
| AMINO ACID FORMULA WITH VITAMINS AND MINERALS WITHOUT LYSINE AND LOW IN TRYPTOPHAN |
GA explore5™ |
VITAFLO AUSTRALIA PTY LIMITED |
Glutaric aciduria type 1 Pyridoxine dependent epilepsy |
Nov 2024 |
Recommended |
| AFLIBERCEPT |
Eylea® |
BAYER AUSTRALIA LTD |
Subfoveal choroidal neovascularisation (CNV) secondary to age-related macular degeneration
(AMD) |
Nov 2024 |
Recommended |
| AFLIBERCEPT |
Eylea® |
BAYER AUSTRALIA LTD |
Diabetic macular oedema (DMO) |
Nov 2024 |
Recommended |
| CLOBETASOL |
Xobet® |
ARROTEX PHARMACEUTICALS PTY LTD |
Corticosteroid responsive dermatoses |
Nov 2024 |
Recommended |
| RIVAROXABAN |
Xarelto® |
ALPHAPHARM PTY LTD |
Prevention of venous thromboembolism Chronic stable atherosclerotic disease |
Nov 2024 |
Recommended |
| RAVULIZUMAB |
Ultomiris® |
ALEXION PHARMACEUTICALS AUSTRALASIA PTY LTD |
Neuromyelitis Optica Spectrum Disorder (NMOSD) |
Nov 2024 |
Recommended |
| TISLELIZUMAB |
Tevimbra® |
BEIGENE AUS PTY LTD |
Oesophageal squamous cell carcinoma (OSCC) |
Nov 2024 |
Recommended |
| GLYCOMACROPEPTIDE AND ESSENTIAL AMINO ACIDS WITH VITAMINS AND MINERALS |
PKU Build 10 |
CORTEX HEALTH PTY LTD |
Phenylketonuria (PKU) |
Nov 2024 |
Recommended |
| NIVOLUMAB |
Opdivo® |
BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD |
Non-small cell lung cancer (NSCLC) |
Nov 2024 |
Not Applicable |
| MARIBAVIR |
Livtencity® |
TAKEDA PHARMACEUTICALS AUSTRALIA PTY. LTD. |
Post-transplant cytomegalovirus (CMV) |
Nov 2024 |
Recommended |
| ESTRADIOL |
Estrogel® |
BESINS HEALTHCARE AUSTRALIA PTY LTD |
Menopausal hormone therapy |
Nov 2024 |
Recommended |
| INCOBOTULINUMTOXINA |
Xeomin® |
MERZ AUSTRALIA PTY LTD |
Chronic sialorrhea |
Nov 2024 |
Deferred |
| SACUBITRIL WITH VALSARTAN |
Entresto® |
NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED |
Chronic heart failure |
Nov 2024 |
Recommended |
| NIVOLUMAB |
Opdivo® |
BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD |
Urothelial carcinoma (UC) |
Nov 2024 |
Recommended |
| RELUGOLIX WITH ESTRADIOL AND WITH NORETHISTERONE ACETATE |
Ryeqo® |
GEDEON RICHTER AUSTRALIA PTY LTD |
Endometriosis |
Nov 2024 |
Advice Provided |
| TRIGLYCERIDES, LONG CHAIN WITH GLUCOSE POLYMER |
ProZero® |
VITAFLO AUSTRALIA PTY LIMITED |
Proven inborn errors of protein metabolism |
Nov 2024 |
Recommended |
| MOMELOTINIB |
Omjjara® |
GLAXOSMITHKLINE AUSTRALIA PTY LTD |
Myelofibrosis with moderate to severe anaemia |
Nov 2024 |
Recommended |
| INCOBOTULINUMTOXINA |
Xeomin® |
MERZ AUSTRALIA PTY LTD |
Moderate to severe spasticity of the upper limb Dynamic equinus foot deformity |
Nov 2024 |
Not Applicable |
| ESTRADIOL AND PROGESTERONE |
Estrogel® Pro |
BESINS HEALTHCARE AUSTRALIA PTY LTD |
Menopausal hormone therapy |
Nov 2024 |
Recommended |
| FOSLEVODOPA WITH FOSCARBIDOPA |
Vyalev® |
ABBVIE PTY LTD |
Advanced Parkinson Disease |
Nov 2024 |
Recommended |
| IVOSIDENIB |
Tibsovo® |
SERVIER LABORATORIES (AUST.) PTY. LTD. |
Bile duct cancer (cholangiocarcinoma) |
Nov 2024 |
Recommended |
| LEVODOPA WITH CARBIDOPA AND ENTACAPONE |
Lecigon® |
STADA PHARMACEUTICALS AUSTRALIA PTY LIMITED |
Advanced Parkinson disease |
Nov 2024 |
Advice Provided |
| DROSPIRENONE WITH ETHINYLESTRADIOL |
|
BAYER AUSTRALIA LTD |
Oral contraceptive Moderate acne vulgaris in women who seek oral contraception Premenstrual
dysphoric disorder in women who have chosen oral contraceptives as their method of
birth control |
Nov 2024 |
Recommended |
| BLINATUMOMAB |
Blincyto® |
AMGEN AUSTRALIA PTY LIMITED |
Measurable residual disease (MRD)-negative B-cell precursor acute lymphoblastic leukaemia
(B-ALL) |
Nov 2024 |
Recommended |